Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Vertex Pharmaceuticals sees FY25 revenue $11.75B-$12.0B, consensus $11.85B Sees FY25 R&D, AIPR&D and SG&A expenses of $4.9B-$5.0B.

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago.

Innocan Pharma Corporation ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of ...

Nvidia stock rallied to a critical level Monday, with Fed Chairman Jerome Powell set to testify in front of Congress.